Your browser doesn't support javascript.
loading
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or, Amit; Thanei, Gian-Andrea; Harp, Christopher; Bernasconi, Corrado; Bonati, Ulrike; Cross, Anne H; Fischer, Saloumeh; Gaetano, Laura; Hauser, Stephen L; Hendricks, Robert; Kappos, Ludwig; Kuhle, Jens; Leppert, David; Model, Fabian; Sauter, Annette; Koendgen, Harold; Jia, Xiaoming; Herman, Ann E.
Affiliation
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: amitbar@pennmedicine.upenn.edu.
  • Thanei GA; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Harp C; Genentech, Inc., South San Francisco, CA, USA.
  • Bernasconi C; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Bonati U; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Cross AH; Washington University School of Medicine, St Louis, MO, USA.
  • Fischer S; Genentech, Inc., South San Francisco, CA, USA.
  • Gaetano L; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Hauser SL; University of California, San Francisco, San Francisco, CA, USA.
  • Hendricks R; Genentech, Inc., South San Francisco, CA, USA.
  • Kappos L; Multiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and Universit
  • Kuhle J; Multiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and Universit
  • Leppert D; Multiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and Universit
  • Model F; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Sauter A; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Koendgen H; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Jia X; Genentech, Inc., South San Francisco, CA, USA.
  • Herman AE; Genentech, Inc., South San Francisco, CA, USA.
EBioMedicine ; 93: 104662, 2023 Jul.
Article de En | MEDLINE | ID: mdl-37354600
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sclérose en plaques chronique progressive / Sclérose en plaques récurrente-rémittente / Sclérose en plaques Type d'étude: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: EBioMedicine Année: 2023 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sclérose en plaques chronique progressive / Sclérose en plaques récurrente-rémittente / Sclérose en plaques Type d'étude: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: EBioMedicine Année: 2023 Type de document: Article